Gulbanu Shaimerdenova

Dr. Gulbanu Shaimerdenova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2024 in International Journal of Reproductive BioMedicine (IJRM)
Verified
Journal Article
Open access
GSGulbanu Shaimerdenova
Gulbanu Shaimerdenova
GAGulzhan Narkenovna Abuova
Gulzhan Narkenovna Abuova
SNSaltanat Kulbayeva Nalibekkyzy
Saltanat Kulbayeva Nalibekkyzy
Background: At the beginning of the Coronavirus disease 2019 (COVID-19) pandemic, studies showed that the risk of severe disease was higher in pregnant women. Objective: This study investigates the characteristics of severe and critical types of COVID-19 coronavirus infection in pregnant women. Materials and Methods: This prospective cross-sectional study compared the medical records of 120 pregnant women with severe and very severe COVID-19 treated at the Infectious Disease Center, Shymkent, Kazakhstan from December 2021 to May 2022. Factors such as time of hospital admission, hospitalization period, maternal comorbidities, age, pregnancy and postpartum complications, pregnancy outcomes, and treatment type were analyzed. Results: 87 (72.5%) pregnant women with severe and 33 (27.5%) with critical type of COVID-19 were included. The following data were obtained when comparing the pregnancy parity of the subjects, depending on the gestational age: in 1–12 wk, the indicator was 3.75 ± 0.95; in 13–27 wk3.00 (Q1-Q3: 2.00–4.00), in 28–40 wk 3.00 (Q1-Q3: 2.00–4.00). Severe COVID-19 coronavirus infection occurs in women with more than a third pregnancy (Me 3.00 [Q1-Q3: 2.00–4.00]). Conclusion: There is a risk of disease progression to severe and critical COVID-19 in pregnant women older than 33 yr of age and at 28–40 wk gestation. Early referral to a doctor in hospital, timely hospitalization, and initiated treatment reduces the risk of aggravation of the patient’s condition and development of formidable complications. Key words: COVID-19, Pregnancy, Infection.

17 May 2023 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GSGulbanu Shaimerdenova
Gulbanu Shaimerdenova
GAGulzhan Narkenovna Abuova
Gulzhan Narkenovna Abuova
SSSerikbayeva Saltanat
Serikbayeva Saltanat
SBSaltanat Baimbetova
Saltanat Baimbetova
AAAtabay Aidana
Atabay Aidana
Background: Coronavirus disease 2019 (COVID-19) is difficult to treat in pregnant women due to pregnancy itself and the lack of standard treatment for the disease. As of August 2021, the etiotropic drug remdesivir has been added to the prescription list for women during gestation. There are few publications in the global scientific community regarding the use of this antiviral drug in pregnant women. Moreover, there are only sporadic scientific studies in Kazakhstan, so the question remains open. Objectives: This study aimed to evaluate the efficacy of remdesivir in pregnant women with probable or confirmed COVID-19. Methods: The study comprehensively examined 120 pregnant women with severe to very severe COVID-19, who were divided into two groups of patients. The study group consisted of women who received remdesivir and standard therapy. The control group included patients who received standard therapy per the protocol. Results: Statistically significant age differences were observed between the main and control groups (P = 0.019). The differences detected were due to a higher frequency in the age group of 33 and 42 years in patients taking remdesivir than in the control group (P = 0.036). Women in the main group (Median = 9.00; Q1 - Q3 = 8.00 - 11.0) had longer hospital stays than the control group (Me = 8.00; Q1 - Q3 = 7.00 - 10.0). This was due to the more severe condition of the patients in this group. There were statistically significant differences in amniotic fluid changes according to ultrasound between the control and main groups (P = 0.013). When comparing the groups in pairs, amniotic fluid was more common in women who received remdesivir (P = 0.316) than in the control group. Our study found that a decrease in temperature to normal levels occurred earlier in the control group (68%) than in the main group. Further SpO2 increases of more than 95% were seen on days 3 - 4 in the main group (71%) and days 1 - 2 in the control group (43%). After three days, there was an improvement in respiratory rate (41.6%) and a reduction in subjective dyspnea (66.6%) in the main group. Conclusions: The study found that repeat mothers have a more severe course of COVID-19. The older age group and the third trimester of pregnancy are risk factors for progression to severe disease.

28 February 2024 in Наука и здравоохранение
Verified
Journal Article
Open access
Gulzhan AbuovaGulzhan Abuova
Gulzhan Abuova
KKKhangeldy K.ZH.
Khangeldy K.ZH.
GSGulbanu Shaimerdenova
Gulbanu Shaimerdenova
ZBZhorakhanova B.A.
Zhorakhanova B.A.
SDSadykhova D.K.
Sadykhova D.K.
Relevance. From 600 thousand to 1.2 million cases of ARVI and influenza are registered annually in Kazakhstan. On the average for the epidemiological season hospitalised with severe and medium - severe course of ARVI - up to 70-80 thousand people, 70% of whom are children under 14 years, including children under 1 year - up to 30-35%, pregnant women -53-55% of the number of pregnant women who fall ill with ARVI, respectively. Treatment of acute respiratory viral infectious disease (ARVI) includes a number of measures and approaches aimed at alleviating symptoms, reducing the duration of the disease and preventing complications. One such drug is enisamia iodide, produced by Pharmak (Ukraine) under the trade name Amizon, registered in the Republic of Kazakhstan as an antiviral agent. Materials and methods. The study is a cohort, clinical, non-interventional, prospective. In the city infectious diseases hospital of Shymkent, clinical trials were conducted on the effectiveness of the antiviral drug enisamia iodide in severe forms of ARVI in adults, in comparison with a group of patients who did not receive etiotropic treatment from December 2022 to January 2023. Results and conclusions. As a result of the treatment, progression of normalization of body temperature was observed by the 4th and 5th days (96% and 98%, respectively). In the comparison group, an improvement in the normalization of body temperature by the 3rd day was registered in 60% of patients. When comparing the main and control groups by bed days, statistically significant differences were established (p=0.049*). Patients with standard therapy stayed in the hospital longer than those who received Amizon additionally. During treatment with Amizon, only 1 case out of 50 developed an adverse event in the form of a minor headache coinciding with the drug intake, which did not require discontinuation of the drug. On the 3rd and 4th days of therapy, statistically significant differences were revealed. Regression of intoxication symptoms (fever, chills, headache, body aches) and catarrhal manifestations occurred much earlier than in the control group. The need to prescribe antibacterial drugs during the use of Amizon was 10%, which indicates its antiviral and antibacterial effect. Актуальность. В Республике Казахстан (РК) ежегодно регистрируется от 600 тысяч до 1,2 млн. случаев ОРВИ и гриппа. В среднем за эпидемиологический сезон госпитализируется с тяжелым и средне - тяжелым течением ОРВИ – до 70-80 тысяч человек, 70% из которых составляют дети до 14 лет, в том числе дети до 1 года – до 30-35%, беременные – 53-55% от числа заболевших ОРВИ беременных соответственно. Лечение острого респираторного вирусного инфекционного заболевания (ОРВИ) включает ряд мер и подходов, направленных на облегчение симптомов, снижение длительности болезни и предотвращение осложнений. Одним из таких препаратов является энисамия иодид, производимый заводом Фармак (Украина) под торговым названием «Амизон», зарегистрированный в РК в качестве противовирусного средства. Материалы и методы. Исследование является когортным, клиническим, неинтерванционным, проспективным. В городской инфекционной больнице г. Шымкента проведены клинические испытания эффективности противовирусного препарата энисамия йодид при тяжелых формах ОРВИ у взрослых, в сравнении с группой пациентов, не получавших этиотропное лечение с декабря 2022 года по январь 2023г. Результаты и выводы. В результате проведенного лечения наблюдалась нормализация температуры тела к 4-му и 5-му дню у 96% и 98% больных соответственно. В группе сравнения нормализация температуры тела к 3-му дню зарегистрирована у 60% больных. При сравнении основной и контрольной групп по койко-дням были установлены статистически значимые различия (p=0,049*). Пациенты со стандартной терапией находились в стационаре дольше, чем те, которые получали Амизон дополнительно. На фоне лечения Амизоном только в 1 случае из 50 развилось нежелательное явление в виде незначительной головной боли, совпадающей по времени с приемом препарата, не потребовавшее отмены препарата. На 3 и 4-й день терапии выявлены статистические значимые различия. Регресс симптомов интоксикации (лихорадка, озноб, головная боль, ломота в теле) и катаральных проявлений происходил значительно раньше, чем в группе контроля....

30 June 2024 in Central Asian Journal of Medical Hypotheses and Ethics
Verified
Journal Article
Open access
DBD. Bekaryssova
D. Bekaryssova
GMG. Mutalipova
G. Mutalipova
GSGulbanu Shaimerdenova
Gulbanu Shaimerdenova
Introduction. Mental disorders, characterized by disturbances in thinking, feeling, and behavior, pose a significant medical and social challenge. They affect a substantial portion of the population, leading to profound health implications and diminished quality of life. Despite the considerable interest in this area, data regarding the prevalence of mental disorders in the Republic of Kazakhstan still need to be made available. This study aims to analyze the trend of mental disorder prevalence in Kazakhstan from 2011 to 2020, considering various factors such as gender, age, and residency. Methods. This study employed an informational and analytical approach. Data from 10 statistical compilations of the Ministry of Health of the Republic of Kazakhstan spanning from 2011 to 2020 were utilized to assess the prevalence of mental disorders. Information about morbidity falling under the category of "mental disorders and behavioral disorders" was incorporated. The data were processed and presented in terms of absolute values and relative indicators. Results and conclusions. Analyzing mental disorder incidence data in Kazakhstan over the ten years revealed several trends. Overall morbidity rates showed a declining trend, notwithstanding some years witnessing minor increases in morbidity. The relative incidence rates also decreased, as evidenced by data per 100,000 population. Primary morbidity demonstrated a general decline, with a notable decrease observed in the first half of the study period. Across age groups, morbidity rates decreased in all categories, with the highest rates observed among adults. Moreover, there was a reduction in morbidity rates in both urban and rural populations, albeit with urban areas consistently exhibiting higher rates than rural areas. These findings could inform the development of interventions aimed at enhancing the mental well-being of the population and improving the management of this medical and social challenge in the future.

18 August 2024 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
GSGulbanu Shaimerdenova
Gulbanu Shaimerdenova
Objectives: Evaluation of the Effectiveness of Developed Algorithms for Managing Pregnant Women and Assessing Severity Using the WHO ABCDE Approach During COVID-19 Among Practicing Physicians Material and methods: To evaluate the effectiveness of the algorithm for managing pregnant women and assessing severity using the WHO ABCDE approach during COVID-19, we analyzed 102 medical records of pregnant patients with COVID-19 who received treatment in infectious disease hospitals and perinatal centers in the city of Shymkent from January to April 2022. Results: Diagnostic errors were made in 22.5% of the sample before the training on the developed algorithms. Following the training sessions, the error rate decreased by 7.8%. Physicians identified errors in the following diagnoses: influenza - 10.8% (11 cases), acute intestinal infections - 4.9% (5 cases), acute cerebrovascular accident, measles, and atypical pneumonia - 1.9% (2 cases each), and Kawasaki disease - 0.9% (1 case). After the training, the incidence of the diagnosis of "Influenza" decreased by 4.9% and "Acute intestinal infections" by 3%. Our findings revealed that the percentage of diagnostic errors (underdiagnosis) significantly dropped from 41.2±6.9% (n=51) to 11.6%±4.9 (p<0.01) (n=43), representing a reduction of more than 3.6 times. The analysis of diagnostic errors related to the underdiagnosis of COVID-19 and the implementation of the algorithm for the management and severity assessment based on the WHO ABCDE approach led to a more than 3.6-fold decrease in cases of delayed diagnosis. Conclusions: The analysis of diagnostic errors related to the underdiagnosis of COVID-19 and the implementation of the management and severity assessment algorithm based on the WHO ABCDE approach led to a more than 3.6-fold reduction in the number of delayed diagnoses.

1 January 2025 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GSGulbanu Shaimerdenova
Gulbanu Shaimerdenova
Gulzhan AbuovaGulzhan Abuova
Gulzhan Abuova
AAArdak Ayazbekov
Ardak Ayazbekov
GTGulzhaukhar Taskynova
Gulzhaukhar Taskynova
DBDana Bekaryssova
Dana Bekaryssova
Background: The coronavirus (COVID-19) pandemic has caused global uncertainty. Recent studies indicate an increased risk of spontaneous abortion, spontaneous preterm labor, and severe maternal and neonatal complications caused by COVID-19. Objectives: The aim of our study is to investigate the impact of COVID-19 infection on maternal and neonatal perinatal outcomes. Methods: This is a non-interventional, analytical clinical study. We conducted a retrospective analysis of 410 histories of pregnant women admitted to hospitals from 2020 to 2022 in the City Infectious Disease Centre and the City Infectious Disease Hospital of Shymkent. Results: In the main group, there were 48 (21.0%) babies, while in the control group, there were 18 (10.5%) babies. A weight above 2500 g was recorded in 79% (182) of newborns in the main group. When comparing the weight of newborns between the groups, we did not find statistically significant differences (P = 0.051). Births of babies weighing more than 2500 g were 2.26 times more common in the control group than in the main group (95% CI: 0.984 - 5.228). A birth height of less than 48 cm was recorded in 1.7% (3) cases in the control group and 13.8% (32) of newborns in the main group (P = 0.002). A birth height greater than 48 cm was recorded in 86.2% (198) of neonates in the main group and 98.3% (84) in the control group. Conclusions: A large systematic review (28 studies involving 790,954 pregnant women, among whom 15,524 were diagnosed with SARS-CoV-2 infection) aimed to investigate the relationship between SARS-CoV-2 infection during pregnancy and the risk of pre-eclampsia. It should also be noted that SARS-CoV-2 during pregnancy increases the likelihood of developing severe pre-eclampsia and HELLP syndrome. In our study, preeclampsia (54 - 13.1%) and HELLP syndrome (4 - 1.1%) were more frequent in the main group than in the comparison group. It should also be noted that frequent complications of COVID-19 in pregnant women included preterm labor (80 - 19.4%) and antenatal fetal death (8 - 2.0%). Analysis of perinatal outcomes revealed that women with COVID-19 infection are significantly more likely to give birth to infants with low growth, prematurity, and lower Apgar scores, and these infants are more likely to stay in the neonatal pathology department compared to those born to women without COVID-19 infection.